A 68-year-old man had recurrent bacteremia by carbapenemase (KPC)-producing resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233566 | PMC |
| http://dx.doi.org/10.1093/ofid/ofab141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for .
Antibiotics (Basel)
December 2024
Microbiology Laboratory, Bicêtre University Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.
Expert Rev Anti Infect Ther
December 2024
Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Türkiye.
Article Synopsis
- * The optimal treatment for certain resistant infections is ceftazidime/avibactam, with other alternatives like imipenem/cilastatin/relebactam and meropenem/vaborbactam serving as backup options, especially for KPC-positive cases.
- * Emerging treatment strategies involve using combinations such as ceftazidime/avibactam with aztreonam for tougher infections, while AI-driven risk models can help predict infection risks in vulnerable patients.
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 -Producing KPC-31, a D179Y Variant of KPC-3.
Open Forum Infect Dis
June 2021
Infectious Diseases Clinic, Department of Clinical and Experimental Medicine, Azienda Universitaria Ospedaliera Pisana, University of Pisa, Pisa, Italy.
A 68-year-old man had recurrent bacteremia by carbapenemase (KPC)-producing resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.
View Article and Find Full Text PDFDefining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
J Pediatric Infect Dis Soc
July 2019
Departments of Pharmacy, Johns Hopkins University School of Medicine, Baltimore, Maryland.
With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism.
View Article and Find Full Text PDFMeropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Bacteremia and Abscess in a Liver Transplant Recipient.
Antimicrob Agents Chemother
January 2019
Division of Infectious Disease and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA
We report a case of a 24-year-old liver transplant recipient who developed hepatic artery thrombosis and graft failure, which was complicated by subphrenic abscess and persistent carbapenemase (KPC)-producing bacteremia. Ceftazidime-avibactam treatment led to emergence of resistance, and alternative combination therapy failed due to persistent infection and toxicity. The infection resolved after initiation of meropenem-vaborbactam, which created a bridge to retransplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!